Scientific Online Resource System

Scripta Scientifica Medica

Metastatic colorectal cancer presenting with malignant pleural effsion - a self-experience study

Ivan Novakov

Abstract

INTRODUCTION: Colorectal cancer (CRC) advanced stage (stage IVA) is characterized by distant metastasis in one organ or in one site. The aim of this study is to present a relatively rare localization of CRC dissemi­nation, i.e. pleural metastases clinically presenting with malignant pleural effusion.

PATIENTS AND METHODS: A total of 12 patients, 10 males and two females at a mean age of 61.4±13.3 years (range, 39-78 years) with malignant pleural effusion because of CRC were included in this four-year study (2012-2016). Physical examination and Karnofsky performance status score were evaluated. Radio­graphic studies were used to establish pleural effusion. Pleural effusion drainage and pleural fluid cytolog­ical examinations were performed. Patients` survival rate was established.

RESULTS: Pleural metastasis developed approximately 1.8±0.7 years after radical operation in all the pa­tients. Patient`s Karnofsky performance status score was ≤50. Pleural effusion evacuation was accomplished by tube thoracostomy in all the patients. The cytological examination established adenocarcinoma cells in the pleural effusion. The mean patient`s survival rate was 3.1±1.9 months.

CONCLUSION: This study described a rare localization of CRC metastasis in the pleural cavity character­ized by an extremely low patient`s survival rate. Scr Sci Med 2017; 49(3): 35-39


Keywords

advanced colorectal cancer stage, malignant pleural effusion, tube thoracostomy, survival

Full Text


References

National Cancer Institute. Colon cancer treatment. Available at: http://www.cancer.gov.

Dominitz JA, Samsa GP, Landsman P, Provenzale D. Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. Cancer. 1998;82(12):2312-20.

Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al.; Gastrointestinal Consortium Panel. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003;124(2):544-60. doi: 10.1053/gast.2003.50044

Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326(10):653-7. doi: 10.1056/ NEJM199203053261001

O`Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420-5. DOI: 10.1093/jnci/ djh275

August DA, Ottow RT, Sugarbaker PH. Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev. 1984;3(4):303-24.

American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med. 2000;162(5):1987-2001. doi: 10.1164/ ajrccm.162.5.ats8-00

Sahn SA. Talc should be used for pleurodesis. Am J Respir Crit Care Med. 2000;162(6):2023-4; discussion 2026. doi: 10.1164/ajrccm.162.6.pc09-00a.

Saffran L, Ost DE, Fein AM, Schiff MJ. Outpatient pleurodesis of malignant pleural effusions using a small-bore pigtail catheter. Chest. 2000;118(2):417- 21. doi: org/10.1378/chest.118.2.417.

1Putnam JB Jr, Walsh GL, Swisher SG, Roth JA, Suell DM, Vaporciyan AA, et al. Outpatient management of malignant pleural effusionby a chronic indwelling pleural catheter. Ann Thorac Surg. 2000;69(2):369-75. doi: org/10.1016/ S0003-4975(99)01482-4.

Martínez-Moragón E, Aparicio J, Sanchis J, Menéndez R, Cruz Rogado M, Sanchis F. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration. 1998;65(2):108-13.

Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest. 2000;117(1):73-8. doi: org/10.1378/chest.117.1.73.

Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129(2):362- 8. doi: 10.1378/chest.129.2.362.




DOI: http://dx.doi.org/10.14748/ssm.v49i3.4051
Array
Article Tools
Email this article (Login required)
About The Author

Ivan Novakov
Department of Special Surgery, Medical University of Plovdiv

Font Size


|